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Abstract - Investigation of hyperhomocysteinemia (HHcy) as an important risk factor for pulmonary thromboembolism 
(PTE), which represents a most dangerous consequence of a unique phenomenon of venous thromboembolism which 
still suffers from sometimes conflicting or inadequately clarified results. The role of homocysteine in the clinical 
manifestation of this life-threatening disease and its treatment (in which any further information may be decisive) 
requires detailed examination. 
The purpose of this study is to determine the differences in HHcy incidence and homocysteinemia levels between 
patients with PTE and healthy persons. The study enrolled 70 patients with PTE and 50 healthy persons. Homocysteine 
was measured using the HPLC method with fluorescent detection and HHcy was defined as homocysteinemia above 12 
μmol/L. Statistical analyses included chi-square and Mann Whitney U tests. The median homocysteinemia value was 
significantly higher (p=0.017) in the patients (12.10 μmol/L) than in the controls (10.35 μmol/L). The comparison of 
HHcy incidence between the patients (51.5%) and controls (30%) revealed a significant difference (p=0.021). In 
patients, homocysteinemia was significantly higher (p=0.002) in men (14.05μmol/L) than in women (10.01 μmol/L). 
HHcy was present in 67.6% of men with PTE, which was significantly higher (p=0.006) than the incidence in women 
with PTE (33.3%). Healthy males had significantly higher (p=0.001) homocysteinemia (12.54 μmol/L) than healthy 
females (9.4 μmol/L). A significant difference (p=0.031) was observed between the incidences of HHcy in healthy males 
(44.0%) and healthy females (16.0%).  
We conclude that the incidence of hyperhomocysteinemia and homocysteinemia are significantly higher in all the 
patients compared with the healthy persons, as well as in both healthy males and males with PTE compared with healthy 
females and female patients. This indicates that HHcy findings in PE are likely to have a clinical importance. 
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INTRODUCTION 
As a rather common cardiovascular emergency, 
pulmonary embolism (PE) resulting from occlusion of 
the pulmonary arterial bed may lead to acute life-
threatening complications (Torbicki et al., 2008). 
Regional registry data show that about 18-208 per 
100000 persons have been diagnosed with pulmonary 
embolism annually (Torbicki et al., 2008). The data 
collected between 1979 and 1999, found a 0.4% 
prevalence of pulmonary embolism among hospita-
lized patients (Torbicki et al., 2008). PE as a potentially 
fatal disease has a higher overall mortality than that in 
patients with acute myocardial infarction, exceeding 
10% at 30 days and 16% at 3 months (Goldhaber et al., 
2003, Goldhaber et al., 1999, Kucher et al., 2006.). 
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Identifying the risk factors for the occurrence and 
recurrence of venous thromboembolism (VTE), 
manifested as pulmonary embolism or/and deep vein 
thrombosis, and defining the place and role of each 
respective parameter, plays a crucial role in risk 
stratification and determination of prevention measure 
against these serious diseases (Zhu et al., 2009).  
Homocysteine is a sulfhydryl amino acid for-
med from the demethylation of dietary methionine 
(Konkle et al., 2008). The studies examining a more 
explicit relationship between elevated plasma ho-
mocysteine concentration and coronary artery di-
seases are much more numerous than those exami-
ning the sometimes conflicting but now more ap-
preciated relationship between hyperhomocysteine-
mia (HHcy) and venous thrombosis. (Bauer et al., 
2005). Homocysteine is considered to be a risk fac-
tor for venous thrombosis as well as for arterial 
thrombosis (Hirsh et al., 2001, Goldhaber et al., 
2008, Kucher et al., 2004).  
The purpose of this study is to determine the 
differences in HHcy incidence and homocysteinemia 
levels between patients with PE and healthy persons. 
MATERIALS AND METHODS 
Our study enrolled 70 patients (37 men and 33 
women) with PE (mean age was 42.5 ± 17.08 years). 
The pulmonary embolism diagnosis was made on the 
basis of well-established clinical criteria (Torbicki et 
al., 2008). Our study detected the following acquired 
risk factors for PE in the participants as the most 
frequent: long immobilization patients (pts) (30%), 
pregnancy/puerperium (22.8%), surgery (18.6%), 
trauma (11.4 %), obesity (6.8%) and hormone 
replacement therapy/oral contraceptive usage (4.5%). 
The family medical history for VTE was 
positive in 23 (33%) patients, while an analysis of 
the personal medical histories revealed that 18 
(26%) patients had already experienced certain epi-
sodes of VTE. Exclusion criteria were the presence 
of the following comorbidities affecting the Hcy 
blood level: renal insufficiency, thyroid dysfunction, 
diabetes mellitus, malignancies as well as drugs 
interfering in homocysteine metabolism. The con-
trol group comprised 50 healthy persons (25 men 
and 25 women) of equivalent age. All the partici-
pants received no supplementation with vitamins 
B6, B12 and folate. 
Blood samples were collected from all the 
participants after 12 h overnight fasting. Following 
venipuncture, samples were kept on ice prior to 
centrifugation in order to lower the increase in the 
Hcy blood level via synthesis in erythrocytes. Sera 
were separated within 45 min and kept at -20°C 
until analysis. The total Hcy concentration was de-
termined by high-performance liquid chromato-
graphy (HPLC) with fluorescent detection (Mir-
kovic et al., 2004). According to recent recommen-
dations, Hcy concentrations above 12 μmol/L were 
considered as HHcy (Herrmann et al., 2006). 
The HHcy incidence between the patients and 
controls was compared by the Chi-square test. Gen-
der-related differences in HHcy incidence between 
groups of patients formed according to stratification 
based on the presence and type of the most frequent 
acquired risk factors for PTE, were evaluated by the 
same test. The distribution of Hcy levels in our study 
did not follow the Gaussian mode. Therefore the 
Mann-Whitney U test was employed to compare the 
median Hcy levels between patients and controls, to 
evaluate gender related variations in Hcy 
concentrations and to test the difference in Hcy levels 
related to the presence of the most frequent acquired 
risk factors for PTE. The Kruskal-Wallis test was used 
to estimate differences in Hcy levels among groups of 
patients formed on the basis of the type of most 
frequent acquired risk factors for PTE. A p-value of 
less than 0.05 was considered to be significant. 
Statistical analyses were performed using the program 
Statgraphics vers. 4.2 (Aslan et al., 2007) 
RESULTS 
HHcy was present in 51.5% of the patients and 30% 
of the controls, revealing a significant difference 
(P=0.021), as illustrated in Fig. 1. The comparison 


















Fig. 1. Comparison of HHcy incidence among patients and














Fig. 2. Comparison of Hcy concentrations among patients and 
controls (statistically significant difference; P=0.017). 
of median Hcy values in patients (12.1 μmol/L) and 
controls (9.6 μmol/L), represented in Fig. 2, 
confirmed a significant difference (P=0.017). 
Fig. 3 illustrates gender related differences in 
HHcy incidence, both in patients and controls. HHcy 
incidence was present in 67.6% of the male PE pts, 
which was significantly higher (p=0.006) than the 
incidence in female PE pts (33.3%). Similarly, in the 
control groups a significant difference (p=0.031) was 
found between the incidence of HHcy in healthy 
males (44.0%) and healthy females (16.0%). The 
analogous relationship between gender and Hcy level 
is presented in Fig. 4. In the PE group, homo-
cysteinemia was significantly higher (p=0.002) in male 
patients (14.1 μmol/L) than in female pts (10.1 
μmol/L). In the control group, males had significantly 
higher (p=0.001) homocysteinemia (12.5 μmol/L) 
than females (9.4 μmol/L). 
Comparing the groups of patients with the positive 
and negative history of previous VTE events, this 
parameter did not prove significant with regard to 
HHcy incidence (60.0% vs. 52.5%) as well as Hcy 
concentrations (15.3 μmol/Lvs. 12.2 μmol/L). Though a 
family history of VTE comparison showed higher 
HHcy incidence and Hcy levels in the group with 
positive family history (54.5% and 13.7μmol/L) than in 
the group with a negative one (46.1% and 11.6μmol/L), 
the level of statistical significance was not exceeded. 
Also, the comparison of HHcy incidence and Hcy 
levels between groups regarding the most frequent ac-
quired risk factor associated with PTE revealed no 
significant differences.  
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Fig. 3. Gender related differences in HHcy incidence between
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Fig. 4. Gender related differences in Hcy levels between
patients and controls. 
 
DISCUSSION 
Plasma homocysteine levels (homocysteinemia) is 
determined by genetic mutations and/or acquired 
disruption in the homocysteine metabolism pathways. 
The most frequent genetic causes of hyperhomo-
cysteinemia are defects in the gene encoding for en-
zymes of homocysteine metabolism (the gene encoding 
for cystatione beta synthase and defects of gene 
encoding for methylenetetrahydrofolate reductase – 
MTHFR – the most common being MTHFR C677T 
polymorphism). The major acquired factors leading to 
hyperhomocysteinemia are nutritional deficiencies of 
folate, vitamin B12, and/or vitamin B6, folate antago-
nist administration (metotrexate, phenytoin), vitamin 
B6 antagonists (estrogen, theophylline), disturbed renal 
function, as well as hypothyroidism (Joffe et al., 2002, 
Mirkovic et al., 2003, Castro et al., 2006, Fonseca et al., 
1999, Colleran et al., 2005, Herrmann et al., 2001). 
Elevated homocysteine concentrations having been 
reported in association with several types of carcinoma, 
including breast, ovarian and pancreatic cancer, as well 
as acute lymphoblastic leukemia. Our study excluded 
participants ever having had any type of malignancy or 
other comorbidity affecting homocysteine metabolism 
(Welch et al., 1998). 
Homocysteine association with atherothrom-
bosis has received much more attention than its 
association with venous thromboembolism, though 
homocysteine is known to induce VTE by means of 
its multiple mechanisms (Welch et al., 1998). Along 
with a toxic effect on the clotting cascade, homo-
cysteine has thrombogenic and toxic effects on the 
vascular endothelium, including injury to the vas-
cular endothelium and antagonism of the synthesis 
and function nitric oxide (den Heijer M et al., 1996, 
Kucher et al., 2004, Hirsh et al., 2001). 
Homocysteine is known to enhance upre-
gulation of IL 8, which leads to enhanced leukocyte 
recruitment, inhibits prostacyclin synthesis, down-
regulates thrombomodulin expression, blocks tissue 
plasminogen activator (t-PA), inhibits plasminogen 
activation, increases platelet adhesion, induces 
tissue factor and factor V activation (Melhem et al., 
2009, D’Angelo et al., 1997). It also suppresses he-
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paran sulfate expression, reduces protein C levels 
(in homocystinuria, homozygous CBS deficiency) 
(D’Angelo et al., 1997) and rapidly incorporates 
into factor Va by activated protein C due to 
homocysteinylation of the cofactor by modification 
free cysteine (Undas et al., 2001). 
As VTE (deep vein thrombosis and pulmonary 
embolism) is considered to be a unique entity 
sharing the same risk factors, the results of our 
study on PE are comparable with those of other 
studies of VTE. Similarly to Bienvenu et al., our 
results demonstrated a significant association bet-
ween fasting plasma homocysteine and VTE. While 
Falcon et al. (1994) reported a high prevalence of 
hyperhomocysteinemia in patients with VTE less 
than 40 years of age who had VTE, our study 
confirmed a high prevalence in all age groups. Our 
results would be even more plausible if we, like 
Falcon et al. (1994), had used post methionine load 
increments of homocysteine (standard methionine 
loading test) along with fasting plasma levels of 
homocysteine. Our results are also comparable with 
the data reported by den Heijer (1996) who con-
firmed mild hyperhomocysteinemia as a risk factor 
for deep vein thrombosis (den Heijer et al., 1996). 
On the other hand, some other studies on 
homocysteine and venous thrombosis have con-
flicting results compared with ours. Brattstrom et 
al. found no significant difference in plasma homo-
cysteine concentrations between 42 patients with 
VTE and healthy control subjects, although male 
patients showed a tendency toward higher plasma 
homocysteine than the male control subjects. 
Though showing negative association with homo-
cysteine and VTE, the data on post-methionine 
found a 3-fold elevated risk of hyperhomocystei-
nemia for thrombosis, which remained non-signifi-
cant, probably due to small sample size (den Heijer 
et al., 1998, Brattström et al., 1991). Another small-
sample-size study on deep venous thrombosis 
(DVT) stated no difference in preload and postload 
homocysteine (Amundsen et al., 1995). An exagge-
rated homocysteine rise following methionine loa-
ding may identify individuals at increased risk of 
vascular disease, as well as individuals with im-
paired homocysteine metabolism not detected by 
fasting homocysteine concentration, and is often 
considered primarily a test of transsulfuration path-
way (Apeland et al., 2003). Fasting homocysteine 
levels are associated more often with remethylation 
defects, while a postload increase of homocysteine 
is more associated with sulfuration defects (den 
Heijer et al., 1998). Though providing strong evi-
dence that hyperhomocysteinemia is an indepen-
dent risk factor for initial episodes of venous 
thrombosis in the general population, this finding 
by den Heijer M et al. (1996) underestimated the 
disorder prevalence, failing to perform a homo-
cysteine analysis after methionine loading (den 
Heijer et al., 1996, Bauer, 2005). The relative risk of 
patients with post-methionine load homocysteine 
concentration exceeding the 90th percentile was 
similar to that of patients with fasting hyper-
homocysteinemia (den Haijer et al., 1996), which 
implies that post-methionine load homocysteine 
should be determined in patients. Determining only 
fasting homocysteine levels enables detection of 
only a portion of patients exposed to a higher risk. 
Only a modest association of VTE risk has been 
found by several meta-analyses in individuals with 
elevated fasting homocysteine levels (Konkle et al., 
2008). While prospective studies associate each increase 
of 5 μmol/L in homocysteine levels with a 27% higher 
odds risk for venous thromboses, retrospective studies 
report 60% higher odds risk for the same homocysteine 
increment (Den Heijer et al., 2005).  
A weak association between total plasma homo-
cysteine and VTE was confirmed by the Physicians’ 
Health Study when participants were confined to 
persons with so-called idiopathic events without 
acquired risk factors in the older male population, 
(Ridker et al., 1997, Bauer, 2005). Likely due to the 
small number of participants, our study could not 
prove the association between hyperhomocysteine-
mia and PE types defined related to the absence or 
presence of most frequent acquired risk factors.  
About 10-20% patients with venous throm-
boembolism are reported to have hyperhomo-
cysteinemia (Bauer, 2005). Though using recent 
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Herrmann W. (2006) recommendations stating 
that homocysteine concentrations above 12 
μmol/L are considered as hyperhomocysteine-
mia, the number of patients with hyperhomo-
cysteinemia in our study was considerably high-
er (51.3%) compared with other studies, which 
might be ascribed to a disagreement in defining 
the upper limits of homocysteine levels applied 
in different studies.  
Moderate hyperhomocysteinemia is registered 
in 13-18% patients with an initial episode of venous 
thrombosis before the age of 45, demonstrated by 
homocysteine measurement obtained with patient 
fasting and following oral methionine load (Falcon 
et al., 1994, Bauer et al., 2005). The Leiden 
Thrombophilia Study reports an elevated homo-
cysteine level exceeding the 95th percentile of the 
control group was found in 10% of patients and 
conferred a two-fold increased risk of thrombosis. 
(den Heijer et al. 1996, Bauer, 2005).  
Various studies, like the study of den Heijer 
(1995) pointed out the role of hyperhomocysteine-
mia as an established risk factor for recurrent 
venous thrombosis in patients between 20-70 years 
of age when compared to the general population 
(den Heijer et al., 1995). An increased recurrence 
rate in patients with hyperhomocysteinemia was 
also reported by Fermo et al, (1995). 
A Dutch study showed that 25% of patients 
with recurrent venous thrombosis had homocys-
teine levels above the 90th percentile of those in 
healthy controls, and the presence of this conferred 
a two-fold increase in risk of recurrence. (den 
Heijer M et al 1996, Bauer, 2005). 
The results of our study in finding statistically 
significant homocysteine levels and a higher 
percentage of hyperhomocysteinemia in men than 
in women, both in the PE and control group, com-
ply with literature data that give 21-25% higher 
homocysteine concentrations in men than in pre-
menopausal women (Fonseca et al., 1999, Cesari et 
al., 2005). 
Assessing the homocysteinemia contribution to 
a potential occurrence of VTE requires the deter-
mination of specific genetic background in each 
patient along with the exclusion of the aforemen-
tioned acquired risk factors for hyperhomo-
cysteinemia (Cesari et al., 2005, Mirkovic et al., 
2003, Diekman et al., 2001, de Lorgeril et al., 1999, 
Castro et al., 2006, Maron et al., 2004, elevated 
homocysteine levels further increase the risk of 
thrombosis in patients with other causes of throm-
bophylia (Konkle et al., 2008, Ridker et al., 1997, 
Kucher et al., 2004). The risk of thrombosis is 
manifoldly increased in patients with idiopathic 
thromboses who were hyperhomocysteinemic and 
had the Factor V Leiden mutation (Bauer, 2005, 
Kucher et al., 2004, den Heijer et al., 1996 ).  
 CONCLUSION 
Our results confirm that hyperhomocysteinemia 
represents a risk factor for the occurrence of 
pulmonary embolism. In order to clarify the hyper-
homocysteinemia role in specific VTE categories, 
such as unprovoked thromboses (without acquired 
risk factors for VTE), especially those occurring in 
younger age groups, multiple and recurrent throm-
boses or combined arterial and venous thromboses, 
further studies with a larger group of patients are 
required. More comprehensive conclusions would 
be contributed by additional investigation that also 
encompass the methionine postloading homocys-
teine test which enables identification of high-risk 
patients that cannot be determined by means of the 
fasting homocysteine test. More plausible results 
may be yielded by further research into the inter-
reaction between genetic factors controlling homo-
cysteine metabolism and other genetic markers of 
thrombophylia, nutritional factors (folate, vitamin 
B6, vitamin B12 deficiencies), comorbidities affec-
ting homocysteine metabolism and acquired risk 
factors for VTE. 
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